1.03  0 (0%)		09-26 16:00
Open: 1.02 High: 1.035 Volume: 118,204		Pre. Close: 1.03 Low: 1.01 Market Cap: 25(M)

Short term
Mid term
Targets	6-month :	1.25	1-year :	1.31
Resists	First :	1.07	Second :	1.12
Pivot price	1.04
Supports	First :	0.98	Second :	0.81
MAs	MA(5) :	1.04	MA(20) :	1.05
	MA(100) :	1.13	MA(250) :	1.15
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	38.8	D(3) :	46.9
RSI	RSI(14): 40.1
52-week	High :	2.09	Low :	0.81

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ENLV ] has closed above bottom band by 23.5%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.04 - 1.04	1.04 - 1.05
Low:	1 - 1	1 - 1.01
Close:	1.02 - 1.03	1.03 - 1.04

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Fri, 26 Sep 2025
D. Boral Capital Maintains Enlivex Therapeutics (ENLV) Buy Recommendation - Nasdaq

Fri, 19 Sep 2025
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Kansas City Star

Thu, 11 Sep 2025
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - Yahoo Finance

Fri, 22 Aug 2025
Enlivex Therapeutics (ENLV) Rating Maintained as Buy by D. Boral Capital | ENLV Stock News - GuruFocus

Mon, 18 Aug 2025
Enlivex Announces Promising Phase IIa Results for Allocetra in Knee Osteoarthritis - TipRanks

Mon, 18 Aug 2025
Enlivex stock soars after positive knee osteoarthritis trial data - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	24 (M)
Shares Float	21 (M)
Held by Insiders	4.6 (%)
Held by Institutions	10.9 (%)
Shares Short	266 (K)
Shares Short P.Month	197 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.8
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34.9 %
Return on Equity (ttm)	-55.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.63
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-1.81
PEG Ratio	0
Price to Book value	1.28
Price to Sales	0
Price to Cash Flow	-1.97

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.